PERTH, Australia – Australian regenerative medicine company Orthocell Ltd. got the validation it needed to move from being a small little-known Western Australian biotech company to move to the global stage via a research collaboration with Depuy Synthes Products for its Ortho-ATI stem cell technology for regenerating tendons and ligaments.
PERTH, Australia – Proposed recommendations to update Australia's intellectual property (IP) system would be disastrous to the biopharma industry and would put a stranglehold on innovation and investment, industry stakeholders said.
PERTH, Australia – Australian regenerative medicine company Orthocell Ltd. got the validation it needed to move from being a small little-known Western Australian biotech company to move to the global stage via a research collaboration with Depuy Synthes Products for its Ortho-ATI stem cell technology for regenerating tendons and ligaments.
PERTH, Australia – Proposed recommendations to update Australia's intellectual property (IP) system would be disastrous to the biopharma industry and would put a stranglehold on innovation and investment, industry stakeholders said.
DUBLIN – Chicago Cubs fans excepted, 2016 was a bad year for many for a whole host of reasons. The travails of the Australian cell therapy developer Mesoblast Ltd. may not have registered broadly, but the firm had a torrid year.
DUBLIN – Chicago Cubs fans excepted, 2016 has been a bad year for many for a whole host of reasons. The travails of the Australian cell therapy developer Mesoblast Ltd. may not have registered broadly, but the firm has had a torrid year.
PERTH, Australia – Drug and device companies in Australia may soon be able to bring their products to market more quickly via a new priority review designation.
